AstraZeneca shared the topline result from the placebo-controlled ... before AZ and its partner Merck were able to cross the ...

AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns ...

AstraZeneca raises its fiscal 2024 guidance for the second consecutive quarter. This upgrade comes despite ongoing legal ...

AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...

AstraZeneca shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the drugmaker's senior executives in China could be implicated in the largest insurance fraud case ...

AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns over a Chinese probe into the UK drugmaker. Traders cited a report from ...

AstraZeneca has upgraded its revenue and earnings guidance for this year. Total revenues and core earnings per share rose 21% ...

Pascal Soriot, CEO of AstraZeneca, said the growth in total revenue and core earnings per share reflected the "increasing ...

Daiichi Sankyo collaboration AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu (trastuzumab deruxtecan) in March 2019 and datopotamab ...